Brokerages Expect LeMaitre Vascular Inc (LMAT) to Post $0.19 Earnings Per Share

Equities analysts predict that LeMaitre Vascular Inc (NASDAQ:LMAT) will post earnings of $0.19 per share for the current quarter, according to Zacks. Three analysts have made estimates for LeMaitre Vascular’s earnings. LeMaitre Vascular also reported earnings of $0.19 per share in the same quarter last year. The business is expected to announce its next quarterly earnings report on Wednesday, April 24th.

On average, analysts expect that LeMaitre Vascular will report full year earnings of $0.84 per share for the current financial year, with EPS estimates ranging from $0.82 to $0.85. For the next fiscal year, analysts anticipate that the business will post earnings of $0.94 per share, with EPS estimates ranging from $0.90 to $1.00. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that follow LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, February 19th. The medical instruments supplier reported $0.24 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.24. The business had revenue of $28.39 million for the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a net margin of 21.73% and a return on equity of 17.71%.

A number of brokerages recently weighed in on LMAT. BidaskClub downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Wednesday, March 27th. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday. Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a research note on Thursday, February 21st. ValuEngine raised shares of LeMaitre Vascular from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Finally, Lake Street Capital reaffirmed a “hold” rating and issued a $24.00 target price on shares of LeMaitre Vascular in a research note on Wednesday, January 23rd. Seven research analysts have rated the stock with a hold rating and two have given a buy rating to the company. LeMaitre Vascular currently has an average rating of “Hold” and a consensus target price of $33.29.

In other news, insider Trent G. Kamke sold 16,604 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The shares were sold at an average price of $29.63, for a total value of $491,976.52. Following the transaction, the insider now owns 19,857 shares in the company, valued at $588,362.91. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.30% of the stock is currently owned by company insiders.

Institutional investors have recently modified their holdings of the company. Texas Permanent School Fund boosted its holdings in LeMaitre Vascular by 4.6% in the fourth quarter. Texas Permanent School Fund now owns 10,380 shares of the medical instruments supplier’s stock valued at $245,000 after acquiring an additional 461 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of LeMaitre Vascular by 2.4% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 20,726 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 480 shares in the last quarter. Bank of Montreal Can boosted its holdings in shares of LeMaitre Vascular by 99.1% during the 4th quarter. Bank of Montreal Can now owns 1,113 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 554 shares in the last quarter. Albion Financial Group UT boosted its holdings in shares of LeMaitre Vascular by 6.5% during the 3rd quarter. Albion Financial Group UT now owns 9,259 shares of the medical instruments supplier’s stock valued at $359,000 after buying an additional 569 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of LeMaitre Vascular by 151.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,513 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 912 shares in the last quarter. Hedge funds and other institutional investors own 76.52% of the company’s stock.

LMAT traded down $0.18 on Tuesday, reaching $28.63. The company had a trading volume of 111,560 shares, compared to its average volume of 137,306. The company has a market capitalization of $572.01 million, a P/E ratio of 34.08, a P/E/G ratio of 2.97 and a beta of 1.15. LeMaitre Vascular has a 52-week low of $21.79 and a 52-week high of $41.28.

The company also recently announced a quarterly dividend, which was paid on Friday, April 5th. Stockholders of record on Friday, March 22nd were issued a $0.085 dividend. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.07. The ex-dividend date of this dividend was Thursday, March 21st. This represents a $0.34 annualized dividend and a dividend yield of 1.19%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 40.48%.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: What are popular range trading strategies?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit